Seagen Inc

F:SGT

Todd E. Simpson is the Chief Financial Officer (CFO) of Seagen Inc., a biotechnology company that focuses on developing and commercializing innovative cancer therapies. In his role as CFO, Simpson is responsible for overseeing the company's financial operations, including financial planning and analysis, accounting, tax, treasury, and investor relations. Before joining Seagen, Todd Simpson had a distinguished career with significant experience in the finance sector, particularly within the biopharmaceutical industry. He has a proven track record of leading financial operations and strategies that support company growth and long-term value creation. Simpson's expertise is not solely limited to finance; he has played critical roles in business development initiatives, capital market strategies, and financial risk management. His leadership style is often noted for being strategic and collaborative, focusing on driving performance and operational efficiency. His professional background and accomplishments at Seagen are a testament to his ability to align financial objectives with strategic company goals, which has been critical in supporting the company’s mission to make a meaningful difference in cancer care through innovative treatments.

Jean I. Liu, J.D., M.S., is a distinguished executive known for her role as an officer at Seagen Inc., a biotechnology company focused on developing and commercializing innovative cancer treatments. Ms. Liu has an extensive background in both legal and corporate governance aspects, which she brings to her role at Seagen. Before joining Seagen, Jean Liu gained significant experience in the biopharmaceutical sector, building a solid foundation in legal, compliance, and strategic matters. She holds a Juris Doctor (J.D.) degree, underscoring her legal expertise, and also has a Master of Science (M.S.) degree, demonstrating her dual capability in both legal and scientific domains. In her role at Seagen, she is involved in leading legal initiatives, overseeing compliance programs, and supporting corporate strategies to aid in the company’s mission to deliver breakthrough therapies to patients. Her work helps guide the company in navigating complex regulatory environments while ensuring the strategic alignment of various organizational goals. Through her leadership, Seagen continues to strengthen its position as a front-runner in cancer treatment innovation.

Dr. Roger D. Dansey, M.D., is a distinguished medical professional and executive in the biotechnology and pharmaceutical industry. He is currently associated with Seagen Inc., a prominent biotechnology company dedicated to developing and commercializing innovative cancer therapies. Dr. Dansey joined Seagen, Inc. in a key leadership role, where he has made significant contributions to the company's mission of advancing cancer treatment through targeted therapies. With a strong medical background, Dr. Dansey plays a crucial role in overseeing clinical development programs and guiding strategic initiatives to enhance the company's research and development capabilities. Prior to his role at Seagen, Dr. Dansey held various significant positions in the pharmaceutical industry, which showcases his extensive experience in oncology development. His career includes leadership roles at major pharmaceutical companies where he oversaw successful clinical trials and was instrumental in the development of several cancer drugs. Dr. Dansey holds an M.D. and brings a wealth of knowledge in clinical research, oncology, and drug development to his work. His leadership and expertise are vital to Seagen's efforts in providing effective and groundbreaking treatments for cancer patients.

David R. Epstein is a notable executive in the biotechnology and pharmaceutical industry, currently serving as the Chief Executive Officer (CEO) of Seagen Inc., a leading biotechnology company focused on developing and commercializing innovative cancer therapies. Mr. Epstein has a wealth of experience in managing and growing biotech and pharmaceutical enterprises. Before joining Seagen, David Epstein held several significant leadership roles in the industry. He worked at Novartis, where he had a distinguished 25-year career. During his tenure at Novartis, he served as the Division Head and CEO of Novartis Pharmaceuticals, where he was instrumental in advancing the company’s strategy and expanding its product pipeline. He also played a critical role in the development and commercialization of numerous successful therapies. David Epstein holds a Bachelor of Science degree in Pharmacy from the Ernest Mario School of Pharmacy at Rutgers University. He also earned a Master of Business Administration from the Columbia University Graduate School of Business. Under his leadership, Seagen continues to be at the forefront of oncology research and drug development, making significant strides in creating treatments that improve outcomes for cancer patients. Epstein is known for his strategic vision, dedication to innovation, and commitment to enhancing patient care through scientific advancement.

Dr. Vaughn B. Himes, Ph.D., is the Executive Vice President and Chief Technology Officer at Seagen Inc., a biotechnology company that specializes in the development and commercialization of innovative cancer therapies. He plays a crucial role in overseeing the company's technical operations, including process development and manufacturing, ensuring that Seagen's therapeutic products are produced efficiently and to the highest quality standards. Dr. Himes brings a wealth of experience in biopharmaceutical manufacturing and technology development to the company, having held various leadership roles in the industry. Before joining Seagen, Dr. Himes accumulated extensive experience in the field. He has previously worked with several leading biotechnology and pharmaceutical companies, which contributed significantly to his expertise in scaling up production processes for biologics. His academic background includes a Ph.D. in a relevant scientific field, equipping him with the technical knowledge and research skills essential for his role. Dr. Himes’ contributions have been integral to advancing Seagen’s mission of developing targeted therapies for cancer patients, aiming to improve treatment outcomes and quality of life. His leadership in technology operations supports the company's strategic goals and helps foster innovation in cancer treatment.

David Caouette is the Executive Vice President of Corporate Communications and Government Affairs at Seagen Inc. In his role, he is responsible for leading the company's communications strategies, including public relations, internal communications, and government affairs. Caouette's work focuses on enhancing Seagen's corporate reputation and leveraging communication channels to support the company's strategic objectives in the biotechnology and pharmaceutical industries. With a wealth of experience in communications and public affairs, he plays a crucial part in shaping and delivering key messages that align with Seagen's mission to develop therapies for cancer patients.

Christopher P. Pawlowicz is an executive associated with Seagen Inc., where he serves in a leadership capacity. With a robust background in biotechnology and pharmaceuticals, Mr. Pawlowicz has been integral in steering operational and strategic initiatives at Seagen, a company renowned for its focus on developing targeted therapies to treat cancer. Leveraging extensive experience in the industry, he plays a crucial role in driving the organization's mission to advance breakthrough therapies that improve patient outcomes. His contributions encompass overseeing core business functions and fostering innovation in scientific endeavors.